ESSA Pharma (EPIX) shares were down more than 65% premarket Friday after the company said it decided to terminate the phase 2 trial evaluating the combination of masofaniten and enzalutamide in patients with metastatic castration-resistant prostate cancer compared with enzalutamide alone.
The company said in a Thursday statement that the trial is unlikely to achieve the primary endpoint as interim data showed that "there was no clear efficacy benefit seen with the combination of masofaniten plus enzalutamide compared to enzalutamide single agent."
The study's primary endpoint is the proportion of patients reaching a PSA90 response and ESSA Pharma said trial data showed a "much higher" rate of PSA90 response in patients treated with enzalutamide monotherapy.
Price: 1.81, Change: -3.39, Percent Change: -65.19
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.